[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545588":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":40,"responsibleParty":62,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"The Third Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening based on maternal factors",null,"Pregnant women with low risk of pre-eclampsia assessment and no suspected pre-eclampsia symptoms in the later period are only followed up at delivery to register the outcome indicators. For pregnant women with high risk of preeclampsia evaluation, it is necessary to register the history of drug use (whether or not to use and the dosage), and follow up to register the outcome index at delivery.",[13],"Diagnostic Test: Screening method",{"label":15,"type":10,"description":16,"interventionNames":17},"Screening based on FMF model","Preeclampsia risk assessment should be carried out at 11-13+6 weeks and 20-36+6 weeks of pregnancy. For low-risk pregnant women (PlGF≥100pg\u002Fml or sFlt-1 \u002FPlGF \\\u003C38), it is suggested to closely monitor maternal blood pressure and conduct routine prenatal examination. The basic information of pregnant women, medical and obstetric history, physical examination information, ultrasonic examination data, serum markers (PlGF, sFlt-1) test results, pre-eclampsia risk assessment results, medication history and so on were registered in the study. For high-risk pregnant women (PlGF\\\u003C100pg\u002Fml or sFlt-1\u002FPlGF ≥ 38), we should pay close attention to the changes of maternal blood pressure and proteinuria. Dynamic monitoring of PlGF or sFlt-1\u002FPlGF should be carried out when necessary, and baseline information should also be registered after joining the group.",[13],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Screening method","All pregnant women in the group were screened for pre-eclampsia risk according to the clinical risk factors listed in NICE Guidelines (2019).",[9],{"type":20,"name":21,"description":25,"armGroupLabels":26,"otherNames":10},"In the first trimester, pregnant women with routine MAP and PLGF (with UtA-PI detection conditions plus UtA-PI) were tested, and the risk of preeclampsia was evaluated based on Bayes rule combined with maternal factors. In the second and third trimester of pregnancy, routine determination of PLGF or sFlt-1\u002FPLGF was used to evaluate the risk of preeclampsia.",[15],[28],{"name":29,"affiliation":5,"role":30},"Dunjin Chen, Professor","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","18928916722","gzdrchen@gzhmu.edu.cn",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Fang He, M.D","13724831279","hefangjnu@126.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"FANG HE","RECRUITING","Guangzhou","Guangdong","510150","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56,58],{"name":57,"role":33,"phone":38,"phoneExt":10,"email":39},"FANG HE, M.D",{"name":59,"role":33,"phone":60,"phoneExt":10,"email":61},"Qingwen Nie, Master","15622149953","qw0621n@163.com",{"type":30,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dunjin Chen","Director of Guangzhou Institute of Obstetrics and Gynecology","100545588","the-project-of-gestational-hypertension-and-preeclampsia-screening-and-prevention-center-100545588",false,"NCT06383858","The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center","The Project of Gestational Hypertension and Preeclampsia Screening and Prevention","Inclusion Criteria:\n\n* 1\\) Pregnant women who have been screened for pre-eclampsia risk according to the clinical risk factors listed in NICE guidelines (2019);\n* 2\\) Based on the authoritative guideline of Figo and the consensus of experts in China, pregnant women who routinely use maternal factor +MAP＋PLGF±UtA-PI in the first trimester or PLGF or sFlt-1\u002FPLGF in the second and third trimesters to assess the risk of preeclampsia.\n* 3\\) Meet any of the above conditions, join the group voluntarily, and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Severe fetal malformation or abnormality (no fetal heartbeat);\n* 2\\) Those who regularly use aspirin before joining the group;\n* 3\\) There are obvious other abnormal signs, laboratory tests or other clinical d• iseases, which are judged by the researcher to be not suitable for participating in researchers;\n* 4\\) Unable to obtain follow-up and delivery information.",true,"FEMALE","18 Years",{"count":76,"type":77},50000,"ESTIMATED","OBSERVATIONAL","Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery.\n\nTherefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance.",[81,82],"Preeclampsia","Maternal Deaths",[81,84,85,86,87],"Placental growth factor (PlGF)","Real-World Study","Screening","Prevention","2024-09-05",{"date":90,"type":91},"2024-09-19","ACTUAL",{"date":93,"type":91},"2023-08-01",{"date":95,"type":77},"2028-12-31",{"name":5,"class":6},1]